SKYLINEDX B.V.

Their core work

SkylineDx is a Rotterdam-based molecular diagnostics SME that develops RNA-based tools for personalized medicine and clinical decision support. Their work centers on translating gene expression profiling and molecular signatures into validated diagnostic products that help clinicians choose the right treatment for individual patients. In oncology, they built a predictive tool for Multiple Myeloma therapy response; in infectious disease, they are developing an RNA signature test that distinguishes bacterial from viral febrile illness at the point of care. Their role in EU projects is that of a commercial partner bringing diagnostic technology from research toward clinical validation and market readiness.

What they specialise in

How they've shifted over time

In their first H2020 project (2016–2020), SkylineDx was squarely focused on haematological oncology — specifically predicting treatment effectiveness in Multiple Myeloma using molecular profiling. No infectious disease keywords appear in that period. By their second project (2020–2026), the explicit keywords shift to "infectious and inflammatory diseases" and "molecular diagnosis," reflecting an expansion of their RNA-based diagnostic platform into acute febrile illness. The underlying technology — RNA molecular signatures — is consistent across both periods, suggesting this is a platform company deliberately applying its core diagnostic engine to new disease areas rather than a company that has changed direction.

SkylineDx is expanding its RNA molecular signature platform from oncology into acute infectious disease, suggesting future collaborations may bridge both domains — particularly projects needing a commercial diagnostic partner with validated translational expertise.

How they like to work

SkylineDx has participated in EU projects exclusively as a consortium partner, never as coordinator, across both projects. Despite a small project count, they have accumulated 34 unique consortium partners across 14 countries — a notably wide network for just two projects — suggesting they join large, diverse consortia rather than small closed teams. This profile points to a specialist contributor that brings a specific commercial diagnostic capability into multi-partner research programmes, rather than an organisation that builds or leads consortia itself.

With 34 unique partners across 14 countries from only 2 projects, SkylineDx operates in large, geographically broad consortia — a typical footprint for Innovation Action projects that span clinical sites, academic labs, and industry partners across Europe. Their network is pan-European in reach.

What sets them apart

SkylineDx occupies a rare niche as a commercial SME that develops and clinically validates RNA expression classifiers — a capability that sits between academic biomarker discovery and large in-vitro diagnostics manufacturers. For consortium builders, they bring the commercial translation layer that academic partners cannot: regulatory-oriented validation, product development experience, and a route to market. Their demonstrated ability to apply the same molecular platform to both oncology and infectious disease makes them a flexible diagnostic technology partner beyond any single disease area.

Highlights from their portfolio

• MMpredict
  The largest project by far (EUR 1.88M EC funding), this Innovation Action aimed to bring a personalised treatment prediction tool for Multiple Myeloma to clinical validation — a commercially significant milestone in haematology diagnostics.
• DIAMONDS
  Running until 2026, this project represents SkylineDx's strategic pivot into infectious disease, applying RNA molecular signatures to one of the most pressing antibiotic stewardship problems: distinguishing bacterial from viral fever at the bedside.